PROPOFOL EMULSION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PROPOFOL

から入手可能:

BAXTER CORPORATION

ATCコード:

N01AX10

INN（国際名）:

PROPOFOL

投薬量:

10MG

医薬品形態:

EMULSION

構図:

PROPOFOL 10MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

20ML/50ML/100ML

処方タイプ:

Prescription

治療領域:

MISCELLANEOUS GENERAL ANESTHETICS

製品概要:

Active ingredient group (AIG) number: 0121833001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2024-01-30

製品の特徴

_PROPOFOL Product Monograph _
_Page 1 of 48_
_ _
PRODUCT MONOGRAPH
PR
PROPOFOL
Propofol Injectable Emulsion, BP
1% w/v
10 mg/mL
Intravenous Emulsion – Anaesthetic - Sedative
Baxter Corporation
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
Date of Revision:
September 29, 2017
Submission Control No: 207653
_PROPOFOL Product Monograph _
_Page 2 of 48_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
..................